Cellerant Therapeutics (United States)

Targeting renal cell carcinoma with a HIF-2 antagonist

Wenfang Chen, Haley Hill, Alana Christie et al. · Nature · 2016 · 697 citations · Full text

Urology, Genitourinary Cancer, Renal Cell Carcinoma +4

On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models

Hyejin Cho, Xinlin Du, James P. Rizzi et al. · Nature · 2016 · 441 citations · Full text

Urology, Oncology, Hif-2α Antagonist +7

A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma

Eli M. Wallace, James P. Rizzi, Guangzhou Han et al. · Cancer Research · 2016 · 310 citations

Ly6d marks the earliest stage of B-cell specification and identifies the branchpoint between B-cell and T-cell development

Matthew A. Inlay, Deepta Bhattacharya, Debashis Sahoo et al. · Genes & Development · 2009 · 308 citations · Full text

Lymphocyte Development, Earliest Stage, Cell Proliferation +21

Identification of the earliest natural killer cell–committed progenitor in murine bone marrow

John W. Fathman, Deepta Bhattacharya, Matthew A. Inlay et al. · Blood · 2011 · 203 citations · Full text